EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

Luca Boscolo Bielo iD, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Giuseppe Curigliano iD

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Luca Boscolo Bielo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Neoplasms, Unknown Primary, Genomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer of unknown primary origin (CUP) poses a significant challenge due to poor clinical outcomes and limited treatment options. As such, further definition of clinicopathological factors and genomic profile to better adapt treatment strategies is required.

Methods

Medical records were interrogated to retrospectively include CUP with available clinical and genomics data at the European Institute of Oncology. Next-generation sequencing (NGS) included targeted panels. Statistical analyses were conducted with R Software 4.2.2.

Results

A total of 44 patients were included. With a median follow-up of 39.46 months (interquartile range [IQR] 35.98-47.41 months), median PFS (mPFS) to first-line regimen was 3.98 months (95% CI 3.22-5.98), with a clinical benefit rate of 26% (95% CI 14%-49%), and disease control rate (DCR) limited to 48.28%. Most patients (26 of 31, 83.87%) received platinum-doublet chemotherapy, with no statistically significant difference between first-line treatment regimens. Median OS (mOS) was 18.8 months (95% CI 12.3-39.9), with a 12-month OS rate of 66% (95% CI 50%-85%). All patients received comprehensive genomic profiling (CGP). For 11 patients, NGS was unsuccessful due to low sample quantity and/or quality. For the remaining, TP53 (n = 16, 48%) and KRAS (n = 10, 30%) represented the most altered (alt) genes. No microsatellite instability was observed (0 of 28), while 6 of 28 (21.43%) tumors carried high TMB (≥10 mutation per megabase). Eight of 33 tumors (24.2%) displayed at least one actionable alteration with potential clinical benefit according to ESCAT. Only 2 of them received targeted therapy matched to genomic alterations, with a combined mPFS of 2.63 months (95% CI 1.84-not evaluable) as third-line regimens. Six patients received anti-PD1/PD-L1 therapy, showing a meaningful mPFS of 13 months (95% CI 2.04-not evaluable).

Conclusion

CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Unknown PrimaryGenomicsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesHigh-Throughput Nucleotide SequencingAdultAged, 80 and overMutationEurope

Stichwörter der Autor:innen

cancer of unknown primarygenomic profilingimmunotherapytreatment options

Autor:innen und Institutionen

  • Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

ORCID-Profile: Luca Boscolo Bielo, Giuseppe Curigliano

Förderung

  • NCI NIH HHS

Zitieren

APA

Boscolo Bielo, L., Belli, C., Crimini, E., Repetto, M., Ascione, L., Pellizzari, G., Santoro, C., Fuorivia, V., Barberis, M., Fusco, N., Rocco, E. G., & Curigliano, G. (2024). Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The Oncologist. https://doi.org/10.1093/oncolo/oyae038

Vancouver

Boscolo Bielo L, Belli C, Crimini E, Repetto M, Ascione L, Pellizzari G, et al. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The Oncologist. 2024. doi:10.1093/oncolo/oyae038

BibTeX
@article{BoscoloBielo2024,
  author = {Boscolo Bielo, Luca and Belli, Carmen and Crimini, Edoardo and Repetto, Matteo and Ascione, Liliana and Pellizzari, Gloria and Santoro, Celeste and Fuorivia, Valeria and Barberis, Massimo and Fusco, Nicola and Rocco, Elena Guerini and Curigliano, Giuseppe},
  title = {Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae038}
}
Kostenlos starten →